

Reinhard Dummer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3486836/reinhard-dummer-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

636
papers

60,428
citations

98
h-index

238
g-index

691
ext. papers

73,537
ext. citations

7.3
avg, IF

7.26
L-index

#	Paper	IF	Citations
636	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101601	2.2	10
635	Advances in the drug management of basal cell carcinoma.. <i>Expert Opinion on Pharmacotherapy</i> , 2022 , 1-10	4	1
634	Cutaneous SCC with orbital invasion: case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 , 36 Suppl 1, 59-62	4.6	2
633	Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.. <i>Dermatology</i> , 2022 , 1-10	4.4	0
632	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.. <i>Lancet, The</i> , 2022 ,	40	18
631	A DNA replication-independent function of pre-replication complex genes during cell invasion in <i>C. elegans</i> .. <i>PLoS Biology</i> , 2022 , 20, e3001317	9.7	1
630	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition.. <i>Frontiers in Oncology</i> , 2022 , 12, 830627	5.3	1
629	Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown. <i>Cancers</i> , 2022 , 14, 2360	6.6	2
628	Eight Years of Real-Life Experience with Smoothened Inhibitors in a Swiss Tertiary Skin Referral Center. <i>Cancers</i> , 2022 , 14, 2496	6.6	1
627	The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.. <i>ESMO Open</i> , 2021 , 7, 100339	6	3
626	Preclinical characterization of a next generation brain permeable, paradox breaker BRAF inhibitor. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
625	Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. <i>BMC Cancer</i> , 2021 , 21, 1244	4.8	0
624	504 A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER) 2021 , 9, A536-A536		0
623	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102229	2.2	39
622	568 Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment 2021 , 9, A597-A597		
621	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.. <i>European Journal of Cancer</i> , 2021 , 162, 22-33	7.5	2
620	Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. <i>Nature Medicine</i> , 2021 , 27, 1789-1796	50.5	10

619	Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression. <i>Cancer Research</i> , 2021 , 81, 6044-6057	10.1	3
618	Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial. <i>Dermatology and Therapy</i> , 2021 , 11, 2225-2234	4.34	2
617	Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	6
616	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , 2021 , 12, 1434	17.4	5
615	Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. <i>Cancer Cell</i> , 2021 , 39, 394-406.e4	24.3	25
614	Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [F]FDG PET/CT. <i>European Radiology</i> , 2021 , 31, 8011-8020	8	5
613	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. <i>Cancer Cell</i> , 2021 , 39, 288-293	24.3	21
612	A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences. <i>British Journal of Dermatology</i> , 2021 , 185, 101-109	4	4
611	Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1162-1164	4.5	2
610	Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9555-9555	2.2	
609	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9507-9507	2.2	6
608	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 655-664	21.7	9
607	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. <i>European Journal of Cancer</i> , 2021 , 149, 37-48	7.5	3
606	Overall survival benefit from tebentafusp in patients with best response of progressive disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9509-9509	2.2	2
605	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021 , 148, 411-421	7.5	6
604	Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome. <i>Genes</i> , 2021 , 12,	4.2	1
603	Tumor-derived GDF-15 to suppress t-lymphocyte recruitment to the tumor microenvironment resulting in resistance to ANTI-PD-1 treatment.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e14532-e14532	2.2	
602	Who's Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma. <i>Cancers</i> , 2021 , 13,	6.6	3

601	Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2021 , 97, 102189	14.4	10
600	Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. <i>British Journal of Cancer</i> , 2021 , 125, 687-698	8.7	4
599	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 848-857	21.7	40
598	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. <i>Cancers</i> , 2021 , 13,	6.6	5
597	Collection and preprocessing of fine needle aspirate patient samples for single cell profiling and data analysis. <i>STAR Protocols</i> , 2021 , 2, 100581	1.4	0
596	Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden. <i>Genes</i> , 2021 , 12,	4.2	1
595	Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
594	Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma. <i>British Journal of Dermatology</i> , 2021 , 184, 345-347	4	
593	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 1763-1771	4.9	0
592	Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1119-1132	4.6	3
591	How to break resistance to hedgehog inhibitors in advanced basal cell carcinoma?. <i>British Journal of Dermatology</i> , 2021 , 184, 359-361	4	6
590	NRAS melanoma tumor formation is reduced by p38-MAPK14 activation in zebrafish models and NRAS-mutated human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2021 , 34, 150-162	4.5	3
589	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 9-23	3.8	3
588	Efficacy and safety of colchicine in inflammatory skin diseases: a retrospective, monocentric study in a large tertiary center. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 104-109	2.8	5
587	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition 2021 , 9,		20
586	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021 , 144, 182-191	7.5	23
585	The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. <i>European Journal of Cancer</i> , 2021 , 144, 215-223	7.5	2
584	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021 , 152, 116-128	7.5	2

583	Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma 2021 ,		5
582	Cutaneous T cell lymphoma. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 61	51.1	10
581	EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. <i>Annals of Oncology</i> , 2021 , 32, 1332-1347	10.3	29
580	Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2225-2238	4.6	2
579	Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4. <i>Nature Communications</i> , 2021 , 12, 5056	17.4	1
578	Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. <i>Laboratory Investigation</i> , 2021 , 101, 1561-1570	5.9	0
577	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021 , 5, 5098-5106	7.8	5
576	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021 , 385, 1196-1206	59.2	63
575	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2021 , 156, 149-163	7.5	2
574	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. <i>European Journal of Cancer</i> , 2021 , 157, 214-224	7.5	14
573	Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center. <i>Oncotarget</i> , 2021 , 12, 125-130	3.3	0
572	Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma.. <i>Oncotarget</i> , 2021 , 12, 2531-2540	3.3	0
571	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. <i>Annals of Oncology</i> , 2020 , 31, 1075-1082	10.3	22
570	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 2242-2252.e7	4.3	11
569	The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma. <i>Histopathology</i> , 2020 , 77, 460-470	7.3	9
568	A Monocentric, Retrospective Analysis of 61 Patients with Generalized Granuloma Annulare. <i>Dermatology</i> , 2020 , 236, 369-374	4.4	7
567	A paracrine activin A-mDia2 axis promotes squamous carcinogenesis via fibroblast reprogramming. <i>EMBO Molecular Medicine</i> , 2020 , 12, e11466	12	21
566	Light-based therapies and scar sarcoidosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e805-e807	4.6	

565	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. <i>Molecular Cancer Research</i> , 2020 , 18, 1560-1573	6.6	3
564	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020 , 133, 120-130	7.5	11
563	Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score. <i>Radiation Oncology</i> , 2020 , 15, 135	4.2	4
562	Targeting complex, adaptive responses in melanoma therapy. <i>Cancer Treatment Reviews</i> , 2020 , 86, 101997	14.4	7
561	Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-10	7.1	11
560	Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. <i>Onc Immunology</i> , 2020 , 9, 1774323	7.2	11
559	Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis. <i>Frontiers in Medicine</i> , 2020 , 7, 290	4.9	4
558	Blockade of programmed cell death protein 1 (PD-1) in Sjögren syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. <i>Onc Immunology</i> , 2020 , 9, 1738797	7.2	13
557	Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102060	14.4	9
556	Evaluation of the minimal erythema dose for UVB and UVA in context of skin phototype and nature of photodermatosis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2020 , 36, 200-207	2.4	5
555	Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2020 , 13, 117-121	2.9	6
554	Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1489-1495	4.6	5
553	Laser Treatment of Accidental Tattoos: Experience at a Tertiary Referral Center. <i>Dermatology</i> , 2020 , 236, 383-389	4.4	2
552	Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'. <i>European Journal of Cancer</i> , 2020 , 131, 100-103	7.5	3
551	Temporal activation of WNT/ β -catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. <i>Oncogene</i> , 2020 , 39, 4132-4154	9.2	9
550	Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer 2020 , 8,		1
549	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy 2020 , 8,		13
548	429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma 2020 , 8, A454-A454		9

547	432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma 2020 , 8, A458-A458		4
546	Targeted Therapies for BRAF-Mutant Metastatic Melanoma 2020 , 1067-1085		
545	Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma. <i>Oncotarget</i> , 2020 , 11, 3473-3483	3.3	1
544	Dermatological Complications of Systemic Therapies for Melanoma 2020 , 1337-1358		
543	Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis. <i>European Journal of Dermatology</i> , 2020 , 30, 699-709	0.8	0
542	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 358-372	21.7	49
541	Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. <i>British Journal of Dermatology</i> , 2020 , 182, 1369-1378	4	45
540	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. <i>European Journal of Cancer</i> , 2020 , 126, 33-44	7.5	74
539	Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. <i>JAMA Oncology</i> , 2020 , 6, 1957-1966	13.4	15
538	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020 , 31, 1435-1448	10.3	49
537	Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'. <i>European Journal of Cancer</i> , 2020 , 140, 154-157	7.5	1
536	The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. <i>European Journal of Cancer</i> , 2020 , 138, 68-76	7.5	6
535	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020 , 26, 1557-1563	50.5	41
534	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 1256-1264	13.4	27
533	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with -mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 5102-5112	12.9	7
532	Activation of CD8 T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. <i>Cancer Immunology Research</i> , 2020 , 8, 1114-1121	12.5	7
531	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1944-1956	14.6	46
530	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. <i>Inflammatory Intestinal Diseases</i> , 2020 , 5, 109-116	2.5	6

529	Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma. <i>Oncologist</i> , 2020 , 25, e1593-e1597	5.7	4
528	LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600E mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. <i>Annals of Oncology</i> , 2020 , 31, S1172	10.3	36
527	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. <i>Melanoma Research</i> , 2020 , 30, 552-561	3.3	2
526	Evolving impact of long-term survival results on metastatic melanoma treatment 2020 , 8,		18
525	Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020 , 10, 1163	5.3	4
524	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. <i>ESMO Open</i> , 2020 , 5,	6	7
523	Recurrent squamous cell carcinoma of the perianal skin: a case report. <i>ESMO Open</i> , 2020 , 5, e000786	6	1
522	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020 , 31, 1449-1461	10.3	19
521	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020 , 383, 1139-1148	59.2	105
520	Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11
519	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2020 , 18, 346	8.5	2
518	Binimetinib in heavily pretreated patients with NRAS-mutant melanoma with brain metastases. <i>British Journal of Dermatology</i> , 2020 , 182, 488-490	4	3
517	Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 74-85	4.5	4
516	Dapsone in a Large Tertiary Center: Outdated Therapeutic Option or Timeless Agent?. <i>Dermatology</i> , 2020 , 236, 183-190	4.4	2
515	Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect. <i>BMC Cancer</i> , 2020 , 20, 300	4.8	10
514	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2020 , 26, 4414-4425	12.9	30
513	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1547-1559	7.4	23
512	Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. <i>Cancers</i> , 2019 , 11,	6.6	4

511	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up <i>Annals of Oncology</i> , 2019 , 30, 1884-1901	10.3	182
510	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019 , 381, 1535-1546	59.2	1260
509	Keratinocytic Malfunction as a Trigger for the Development of Solar Lentigines. <i>Dermatopathology (Basel, Switzerland)</i> , 2019 , 6, 1-11	1.9	8
508	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019 , 109, 61-69	7.5	18
507	Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy. <i>JAMA Oncology</i> , 2019 , 5, 730-731	13.4	1
506	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology, The</i> , 2019 , 20, 1083-1097	21.7	356
505	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced - or -mutated melanoma. <i>Oncotarget</i> , 2019 , 10, 1850-1859	3.3	12
504	Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti-PD-1 monoclonal antibody. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e381-e383	4.6	
503	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). <i>European Journal of Cancer</i> , 2019 , 114, 117-127	7.5	64
502	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 701-710	21.7	23
501	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1314-1322	9.7	17
500	Reply to E. Hindil and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1356-1358	2.2	1
499	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019 , 30, 1154-1161	10.3	93
498	Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. <i>European Journal of Cancer</i> , 2019 , 112, 29-31	7.5	12
497	Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5 mice. <i>Nature Communications</i> , 2019 , 10, 1492	17.4	58
496	Radiotherapy in Periocular Cutaneous Malignancies: A Retrospective Study. <i>Dermatology</i> , 2019 , 235, 234-239	4.4	6
495	Yin Yang 1 Orchestrates a Metabolic Program Required for Both Neural Crest Development and Melanoma Formation. <i>Cell Stem Cell</i> , 2019 , 24, 637-653.e9	18	24
494	Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients 2019 , 7, 50		28

493	Serum S100B Levels in Melanoma. <i>Methods in Molecular Biology</i> , 2019 , 1929, 691-700	1.4	7
492	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019 , 119, 1-10	7.5	79
491	Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 799-809	5.9	9
490	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019 , 119, 97-106	7.5	27
489	FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). <i>Hematological Oncology</i> , 2019 , 37, 286-288	1.3	1
488	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019 , 10, 3163	17.4	113
487	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389	21.7	88
486	Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019 , 118, 10-34	7.5	152
485	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of -mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019 , 25, 6852-6867	12.9	33
484	MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA. <i>Neuro-Oncology Advances</i> , 2019 , 1, i17-i17	0.9	78
483	SMAD signaling promotes melanoma metastasis independently of phenotype switching. <i>Journal of Clinical Investigation</i> , 2019 , 129, 2702-2716	15.9	28
482	Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7539-7539	2.2	3
481	Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9575-9575	2.2	1
480	Melanoma patients with additional primary cancers: a single-center retrospective analysis. <i>Oncotarget</i> , 2019 , 10, 3373-3384	3.3	1
479	Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease. <i>Oncotarget</i> , 2019 , 10, 6647-6650	3.3	5
478	Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma. <i>Oncotarget</i> , 2019 , 10, 6509-6525	3.3	1
477	Iatrogenic tattoos after acupuncture: successful outcome after treatment with QS Ruby Laser: A case report and review of literature. <i>Laser Therapy</i> , 2019 , 28, 139-144	0.8	
476	Targeted Therapies for BRAF-Mutant Metastatic Melanoma 2019 , 1-19		

475	Iatrogenic tattoos after acupuncture: successful outcome after treatment with QS Ruby Laser: A case report and review of literature. <i>Laser Therapy</i> , 2019 , 28, 139-144	0.8	1
474	Dermatological Complications of Systemic Therapies for Melanoma 2019 , 1-22		
473	Sustainable responses in metastatic melanoma patients with/without brain metastases after immunotherapy induced CR.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e21042-e21042	2.2	
472	Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma. <i>Melanoma Research</i> , 2019 , 29, 648-654	3.3	3
471	How I treat metastatic melanoma. <i>ESMO Open</i> , 2019 , 4, e000509	6	1
470	TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T-CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST-HOC ANALYSIS OF THE MAVORIC STUDY. <i>Hematological Oncology</i> , 2019 , 37, 285-286	1.3	3
469	Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2019 , 42, 29-32	5	29
468	Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. <i>Journal of Immunotherapy</i> , 2019 , 42, 89-93	5	7
467	Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. <i>Melanoma Research</i> , 2019 , 29, 65-69	3.3	19
466	Proteomic identification of a marker signature for MAPKi resistance in melanoma. <i>EMBO Journal</i> , 2019 , 38, e95874	13	11
465	Cutaneous squamous cell carcinomas on special locations: perioral, periocular and genital area. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33 Suppl 8, 21-24	4.6	3
464	Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. <i>Cancer Immunology Research</i> , 2019 , 7, 77-85	12.5	61
463	The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 686-692	4.6	11
462	Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019 , 106, 12-23	7.5	111
461	Potassium Iodide for Cutaneous Inflammatory Disorders: A Monocentric, Retrospective Study. <i>Dermatology</i> , 2019 , 235, 137-143	4.4	4
460	Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 667-675	4.6	11
459	The PROCLIFI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019 , 181, 350-357	4	66
458	E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. <i>Cancer Discovery</i> , 2018 , 8, 568-581	24.4	41

457	Diagnostic value of F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018 , 96, 64-72	7.5	14
456	NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis. <i>Bioinformatics</i> , 2018 , 34, 107-108	7.2	11
455	Methadone-Not a magic bullet in melanoma therapy. <i>Experimental Dermatology</i> , 2018 , 27, 694-696	4	5
454	Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. <i>European Journal of Cancer</i> , 2018 , 93, 147-149	7.5	8
453	A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. <i>Neoplasia</i> , 2018 , 20, 218-225	6.4	18
452	Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 926-934	4.6	17
451	Development of encorafenib for BRAF-mutated advanced melanoma. <i>Current Opinion in Oncology</i> , 2018 , 30, 125-133	4.2	69
450	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. <i>Nature Medicine</i> , 2018 , 24, 144-153	50.5	374
449	The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. <i>Journal of Dermatological Science</i> , 2018 , 90, 343-356	4.3	8
448	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 603-615	21.7	451
447	Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e7-e8	4.6	2
446	Ipilimumab and early signs of pulmonary toxicity in patients with metastatic melanoma: a prospective observational study. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 127-134	7.4	22
445	Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 372-381	4.6	102
444	Phase I, open-label study of pasireotide in patients with wild type and -wild type, unresectable and/or metastatic melanoma. <i>ESMO Open</i> , 2018 , 3, e000388	6	4
443	Toward Minimal Residual Disease-Directed Therapy in Melanoma. <i>Cell</i> , 2018 , 174, 843-855.e19	56.2	256
442	Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. <i>Clinical Proteomics</i> , 2018 , 15, 13	5	8
441	Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study. <i>Acta Dermato-Venereologica</i> , 2018 , 98, 835-841	2.2	10
440	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1192-1204	21.7	239

439	Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread. <i>Science Advances</i> , 2018 , 4, eaat4758	14.3	43
438	Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. <i>Melanoma Research</i> , 2018 , 28, 442-450	3.3	8
437	Immunological effects of BRAF+MEK inhibition. <i>OncolImmunology</i> , 2018 , 7, e1468955	7.2	37
436	Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. <i>Journal of Clinical Investigation</i> , 2018 , 128, 5531-5548	15.9	22
435	Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 108-108	2.2	94
434	A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2586-2586	2.2	6
433	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9502-9502	2.2	43
432	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9504-9504	2.2	19
431	Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9508-9508	2.2	27
430	Adverse events of special interest in the phase 3 COLUMBUS study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9567-9567	2.2	2
429	A prognostic gene-signature based identification of high-risk thin melanomas.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21575-e21575	2.2	2
428	The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21588-e21588	2.2	9
427	Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. <i>European Journal of Dermatology</i> , 2018 , 28, 736-749	0.8	3
426	Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. <i>European Journal of Dermatology</i> , 2018 , 28, 775-783	0.8	11
425	BRAF-mutant Melanoma □The COLUMBUS Trial. <i>European Oncology and Haematology</i> , 2018 , 14, 78	0.1	
424	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18609-e18609	2.2	
423	Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9579-9579	2.2	1
422	Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study. <i>Blood</i> , 2018 , 132, 1646-1646	2.2	

421	Individualized treatment approaches for Langerhans cell histiocytosis. <i>British Journal of Dermatology</i> , 2018 , 178, 1423-1424	4	1
420	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3441-3449	2.2	137
419	The dynamics of medical care in skin cancers. <i>Current Opinion in Oncology</i> , 2018 , 30, 105-106	4.2	
418	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. <i>Cell Reports</i> , 2018 , 25, 3564-3572.e4	10.6	30
417	Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. <i>Lancet Oncology, The</i> , 2018 , 19, e720-e725	21.7	23
416	The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. <i>Current Oncology Reports</i> , 2018 , 20, 87	6.3	68
415	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. <i>European Journal of Cancer</i> , 2018 , 104, 201-209	7.5	22
414	SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. <i>BMC Medical Informatics and Decision Making</i> , 2018 , 18, 89	3.6	9
413	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1480-1492	21.7	680
412	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1315-1327	21.7	291
411	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. <i>European Journal of Cancer</i> , 2018 , 98, 10-16	7.5	34
410	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. <i>Cancer Cell</i> , 2018 , 34, 69-84.e14	24.3	71
409	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 393-403	21.7	69
408	More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. <i>European Journal of Cancer</i> , 2017 , 75, 313-322	7.5	25
407	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 435-445	21.7	240
406	Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 683-695	7.4	46
405	Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?. <i>Melanoma Research</i> , 2017 , 27, 231-237	3.3	11
404	Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1638-1640	4.6	8

403	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017 , 5, 417-424	12.5	241
402	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. <i>Annals of Oncology</i> , 2017 , 28, 1380-1387	10.3	85
401	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017 , 23, 5339-5348	12.9	101
400	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 1977-1984	4.9	11
399	Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome). <i>Case Reports in Dermatology</i> , 2017 , 9, 74-79	1.1	5
398	Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. <i>Oncologist</i> , 2017 , 22, 749-753	5.7	28
397	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017 , 390, 555-566	4.0	303
396	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017 , 376, 2211-2222	59.2	739
395	Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. <i>Melanoma Research</i> , 2017 , 27, 358-368	3.3	14
394	Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1841-1847	4.6	8
393	A review of binimetinib for the treatment of mutant cutaneous melanoma. <i>Future Oncology</i> , 2017 , 13, 1755-1766	3.6	24
392	Metastatic melanoma moves on: translational science in the era of personalized medicine. <i>Cancer and Metastasis Reviews</i> , 2017 , 36, 7-21	9.6	15
391	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Szary syndrome - Update 2017. <i>European Journal of Cancer</i> , 2017 , 77, 57-74	7.5	240
390	Sox2 is dispensable for primary melanoma and metastasis formation. <i>Oncogene</i> , 2017 , 36, 4516-4524	9.2	20
389	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , 2017 , 116, 1141-1147	8.7	80
388	Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages. <i>EMBO Molecular Medicine</i> , 2017 , 9, 27-45	12	17
387	The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. <i>European Journal of Cancer</i> , 2017 , 86, 101-105	7.5	41
386	A practical guide to the handling and administration of talimogene laherparepvec in Europe. <i>OncoTargets and Therapy</i> , 2017 , 10, 3867-3880	4.4	24

385	Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. <i>Annals of Oncology</i> , 2017 , 28, v429-v430	10.3	23
384	Oestrogen receptor expression in melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1399-1400	4.6	4
383	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017 , 8, 592	17.4	122
382	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1813-1823	59.2	778
381	MEK inhibition and immune responses in advanced melanoma. <i>Oncotarget</i> , 2017 , 6, e1335843	7.2	9
380	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1345-1356	59.2	2030
379	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1011-1029	12	49
378	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. <i>Cell</i> , 2017 , 170, 1109-1119.e10	56.2	762
377	HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2443-2444	4.3	8
376	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. <i>Cancer Medicine</i> , 2017 , 6, 1904-1914	4.8	13
375	BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. <i>Hematological Oncology</i> , 2017 , 35, 77-78	1.3	1
374	RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. <i>Hematological Oncology</i> , 2017 , 35, 245-247	1.3	1
373	PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. <i>Hematological Oncology</i> , 2017 , 35, 247-248 ¹⁻³		2
372	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017 , 28, 2581-2587	10.3	129
371	Electrical Impedance Spectroscopy in Skin Cancer Diagnosis. <i>Dermatologic Clinics</i> , 2017 , 35, 489-493	4.2	40
370	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. <i>European Journal of Cancer</i> , 2017 , 86, 334-348	7.5	146
369	low neurotrophin receptor CD271 regulates phenotype switching in melanoma. <i>Nature Communications</i> , 2017 , 8, 1988	17.4	43
368	Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma. <i>Case Reports in Dermatology</i> , 2017 , 9, 65-68	1.1	13

367	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017 , 82, 80-91	7.5	55
366	Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. <i>Journal of Dermatological Treatment</i> , 2017 , 28, 431-442	2.8	49
365	The safety of anti PD-1 therapeutics for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 41-53	4.1	13
364	Developments in targeted therapy in melanoma. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 581-593	3.6	28
363	ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, e100-e101	4.6	12
362	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017 , 86, 37-45	7.5	106
361	Critical aspects to achieve a high-quality melanoma clinic. <i>Current Opinion in Oncology</i> , 2017 , 29, 145-150	4.2	5
360	Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the Phase 3 ALCANZA study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7517-7517	2.2	3
359	Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9523-9523	2.2	15
358	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9524-9524	2.2	14
357	Hyperproliferative keratinocytic cutaneous adverse events and inflammatory palmoplantar erythrodysesthesia in melanoma patients treated with encorafenib compared to other BRAF inhibitors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9590-9590	2.2	1
356	NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21035-e21035	2.2	1
355	SECOMBIT (sequential combo immuno and target therapy study): A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with metastatic melanoma and BRAF mutation.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS9598-TPS9598	2.2	3
354	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. <i>Oncotarget</i> , 2017 , 8, 69204-69218	3.3	15
353	Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma. <i>Annals of Oncology</i> , 2017 , 28, 1673-1675	10.3	8
352	The value of 18F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2076-2076	2.2	
351	Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. <i>Journal of Clinical Oncology</i> , 2016 , 34, e93-6	2.2	5
350	Sonidegib for the treatment of advanced basal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1963-8	4	11

349	Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 339-342	4.3	27
348	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. <i>Oncologist</i> , 2016 , 21, 1218-1229	5.7	86
347	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. <i>Oncolmmunology</i> , 2016 , 5, e1238557	7.2	89
346	Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. <i>Scientific Reports</i> , 2016 , 6, 29914	4.9	70
345	appendix 2: Cutaneous melanoma (2): eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Melanoma). <i>Annals of Oncology</i> , 2016 , 27, v136-v137	10.3	8
344	A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. <i>ESMO Open</i> , 2016 , 1, e000003	6	19
343	Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K mutant cutaneous melanoma. <i>Annals of Oncology</i> , 2016 , 27, vi575	10.3	26
342	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 113-125.e5	4.5	94
341	PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo. <i>Clinical Cancer Research</i> , 2016 , 22, 5818-5828	12.9	53
340	Efficacy and safety of oral alitretinoin in severe oral lichen planus--results of a prospective pilot study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 293-8	4.6	16
339	Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. <i>Clinical Cancer Research</i> , 2016 , 22, 2020-31	12.9	44
338	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. <i>Cancer Cell</i> , 2016 , 29, 270-284	24.3	149
337	Noncutaneous Melanomas: A Single-Center Analysis. <i>Dermatology</i> , 2016 , 232, 22-9	4.4	11
336	Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. <i>European Journal of Cancer</i> , 2016 , 55, 111-21	7.5	70
335	Localized Hair Repigmentation in a 91-Year-Old Woman. <i>JAMA Dermatology</i> , 2016 , 152, 81-2	5.1	4
334	Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2016 , 22, 4023-9	12.9	120
333	Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. <i>Blood</i> , 2016 , 128, 182-182	2.2	10
332	The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3026-3026	2.2	3

331	Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9500-9500	2.2	22
330	Derivation and validation of a prediction scale for response to PD-1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9514-9514	2.2	2
329	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9526-9526	2.2	2
328	Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9532-9532	2.2	2
327	Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9538-9538	2.2	1
326	Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9549-9549	2.2	9
325	Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9568-9568	2.2	68
324	A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS9598-TPS9598	2.2	6
323	PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. <i>Oncotarget</i> , 2016 , 7, 75551-75560	3.3	15
322	Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration. <i>Oncotarget</i> , 2016 , 7, 83554-83569	3.3	31
321	The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. <i>Swiss Medical Weekly</i> , 2016 , 146, w14279	3.1	28
320	Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. <i>Oncotarget</i> , 2016 , 7, 77163-77174	3.3	39
319	An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. <i>British Journal of Dermatology</i> , 2016 , 175, 966-978	4	4
318	Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. <i>British Journal of Dermatology</i> , 2016 , 174, 823-30	4	19
317	Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors. <i>British Journal of Dermatology</i> , 2016 , 174, 463	4	2
316	Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial. <i>JAMA Dermatology</i> , 2016 , 152, 837-9	5.1	20
315	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016 , 22, 5487-5496	12.9	373
314	Nevoid Basal Cell Carcinoma Syndrome: Report from the Zurich Nevoid Basal Cell Carcinoma Syndrome Cohort. <i>Dermatology</i> , 2016 , 232, 285-92	4.4	13

313	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016 , 60, 210-25	7.5	391
312	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016 , 60, 190-209	7.5	412
311	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016 , 67, 46-54	7.5	54
310	A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis. <i>Cell Reports</i> , 2016 , 15, 1884-92	10.6	10
309	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016 , 375, 1845-1855	59.2	870
308	MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. <i>European Journal of Cancer</i> , 2016 , 65, 130-8	7.5	36
307	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016 , 29, 404-16	4.5	63
306	Resilience in patients and spouses faced with malignant melanoma. A qualitative longitudinal study. <i>European Journal of Cancer Care</i> , 2016 , 25, 122-31	2.4	11
305	Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. <i>PLoS Genetics</i> , 2015 , 11, e1004877	6	59
304	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 908-18	21.7	1151
303	Hedgehog signaling in basal cell carcinoma. <i>Journal of Dermatological Science</i> , 2015 , 78, 95-100	4.3	40
302	Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. <i>Immunity</i> , 2015 , 42, 767-77	32.3	97
301	Brentuximab as a treatment for CD30+ mycosis fungoides and Szary syndrome. <i>JAMA Dermatology</i> , 2015 , 151, 73-7	5.1	43
300	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 522-30	21.7	842
299	Recent advances in primary cutaneous T-cell lymphoma. <i>Current Opinion in Oncology</i> , 2015 , 27, 128-33	4.2	17
298	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , 2015 , 16, 1389-98	21.7	162
297	profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. <i>Oncolmmunology</i> , 2015 , 4, e988458	7.2	7
296	Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4077-84	2.2	21

295	Versican upregulation in S ₂ ary cells alters growth, motility and resistance to chemotherapy. <i>Leukemia</i> , 2015 , 29, 2024-32	10.7	14
294	Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2132-42	6.1	25
293	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. <i>Cell</i> , 2015 , 162, 1242-56	56.2	365
292	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015 , 350, 207-211	33.3	1583
291	The Genetic Evolution of Melanoma from Precursor Lesions. <i>New England Journal of Medicine</i> , 2015 , 373, 1926-36	59.2	587
290	Improved overall survival in melanoma with combined dabrafenib and trametinib. <i>New England Journal of Medicine</i> , 2015 , 372, 30-9	59.2	1723
289	PI3K signalling is required for a TGF β -induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells. <i>Experimental Dermatology</i> , 2015 , 24, 22-8	4	49
288	3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3667-3674	7.5	44
287	3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. <i>European Journal of Cancer</i> , 2015 , 51, S667-S668	7.5	7
286	Melanoma's next top model, it is in the air. <i>Experimental Dermatology</i> , 2015 , 24, 659-60	4	8
285	TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. <i>Scientific Reports</i> , 2015 , 5, 11200	4.9	102
284	Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?. <i>Melanoma Research</i> , 2015 , 25, 461-9	3.3	18
283	Laser treatment of solar lentigines on dorsum of hands: QS Ruby laser versus ablative CO2 fractional laser - a randomized controlled trial. <i>European Journal of Dermatology</i> , 2015 , 25, 122-6	0.8	15
282	Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. <i>Journal of Dermatology</i> , 2015 , 42, 927-8	1.6	
281	A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. <i>British Journal of Dermatology</i> , 2015 , 173, 1462-70	4	17
280	A new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. <i>Experimental Dermatology</i> , 2015 , 24, 377-80	4	21
279	Diffuse Cutaneous Melanosis Associated with Malignant Melanoma. <i>Annals of Dermatology</i> , 2015 , 27, 780-1	0.4	
278	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. <i>PLoS ONE</i> , 2015 , 10, e0139438	3.7	23

277	Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma. <i>BioMed Research International</i> , 2015 , 2015, 432479	3	3
276	Achievements and challenges of molecular targeted therapy in melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 177-86	7.1	29
275	Curing advanced melanoma by 2025. <i>Current Opinion in Oncology</i> , 2015 , 27, 125-7	4.2	4
274	Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. <i>Genome Biology</i> , 2015 , 16, 42	18.3	48
273	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015 , 373, 23-34	59.2	5047
272	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 716-28	21.7	245
271	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncology, The</i> , 2015 , 16, 729-36	21.7	161
270	Transcriptional repression of IFN γ by ATF2 confers melanoma resistance to therapy. <i>Oncogene</i> , 2015 , 34, 5739-48	9.2	14
269	A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. <i>Pharmacology Research and Perspectives</i> , 2015 , 3, e00113	3.1	17
268	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015 , 26 Suppl 5, v126-32	10.3	262
267	Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations. <i>Cancer Research</i> , 2015 , 75, 4817-29	10.1	36
266	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Dereglulation. <i>Cell Reports</i> , 2015 , 11, 1458-73	10.6	37
265	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. <i>Nature Communications</i> , 2015 , 6, 6051	17.4	211
264	Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 1289-97	12.9	64
263	Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3012-3012	2.2	17
262	Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3068-3068	2.2	3
261	A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9007-9007	2.2	37
260	Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9024-9024	2.2	14

259	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9040-9040	2.2	2
258	Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9044-9044	2.2	1
257	A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20044-e20044	2.2	1
256	A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS9081-TPS9081	2.2	8
255	Data mining The Cancer Genome Atlas in the era of precision cancer medicine. <i>Swiss Medical Weekly</i> , 2015 , 145, w14183	3.1	27
254	Tumor Staging in Dermatology 2015 , 103-118		
253	Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20064-e20064	2.2	
252	Composite assessment of treatment response in patients (pts) with locally advanced basal cell carcinoma (laBCC): Sonidegib efficacy using two sets of response criteria.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20055-e20055	2.2	
251	External beam radiotherapy of extramammary Paget disease. <i>Cutis</i> , 2015 , 95, 109-12	0.4	5
250	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. <i>European Journal of Cancer</i> , 2014 , 50, 406-10	7.5	21
249	Clinical implications of distinct metastasizing preferences of different melanoma subtypes. <i>European Journal of Dermatology</i> , 2014 , 24, 236-41	0.8	13
248	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , 2014 , 15, 323-32	21.7	753
247	Metastatic melanoma cell lines do not secrete IL-1 β but promote IL-1 β production from macrophages. <i>Journal of Dermatological Science</i> , 2014 , 74, 167-9	4.3	11
246	Primary cutaneous follicle center lymphoma with diffuse CD30 expression: a report of 4 cases of a rare variant. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 548-54	4.5	16
245	Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. <i>European Journal of Cancer</i> , 2014 , 50, 774-83	7.5	116
244	An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. <i>Translational Oncology</i> , 2014 , 7, 206-12	4.9	9
243	Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. <i>European Journal of Cancer</i> , 2014 , 50, 611-21	7.5	218
242	Coexpression of SOX10/CD271 (p75(NTR)) and β -Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients. <i>Dermatopathology (Basel, Switzerland)</i> , 2014 , 1, 35-46	1.9	3

241	Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sary syndrome). <i>Annals of Oncology</i> , 2014 , 25, 1807-1812	10.3	32
240	Emerging drugs and combination strategies for basal cell carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2014 , 19, 353-65	3.7	19
239	Basal cell carcinomas in a tertiary referral centre: a systematic analysis. <i>British Journal of Dermatology</i> , 2014 , 171, 1066-72	4	24
238	To B-(RAF) or not to be. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 1200-1201	4.3	
237	Novel therapies for cutaneous T-cell lymphoma: what does the future hold?. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 457-67	5.9	19
236	Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. <i>Annals of Oncology</i> , 2014 , 25, 700-706	10.3	40
235	Transient MEK inhibitor-associated retinopathy in metastatic melanoma. <i>Annals of Oncology</i> , 2014 , 25, 1437-1441	10.3	83
234	Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. <i>British Journal of Dermatology</i> , 2014 , 171, 891-4	4	21
233	A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2014 , 20, 1900-9	12.9	172
232	New diagnostic method for lesions with transepidermal melanocytic migration. <i>JAMA Dermatology</i> , 2014 , 150, 654-6	5.1	2
231	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology, The</i> , 2014 , 15, 297-304	21.7	49
230	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA9008-LBA9008	3.2	13
229	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA9008-LBA9008	3.2	22
228	TG1042 (Adenovirus-interferon-)in primary cutaneous B-cell lymphomas: a phase II clinical trial. <i>PLoS ONE</i> , 2014 , 9, e83670	3.7	20
227	Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma. <i>PLoS ONE</i> , 2014 , 9, e112535	3.7	17
226	Primary Cutaneous B-Cell Lymphomas 2014 , 353-364		1
225	Basal cell carcinoma: a paradigm for targeted therapies. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1307-18	4	11
224	Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042. <i>Journal of Translational Medicine</i> , 2013 , 11, 226	8.5	10

223	Treating basal-cell carcinoma in a real life setting. <i>Lancet Oncology, The</i> , 2013 , 14, 572-3	21.7	2
222	Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. <i>European Journal of Cancer</i> , 2013 , 49, 386-94	7.5	104
221	Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 92-6	1.6	35
220	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. <i>Lancet Oncology, The</i> , 2013 , 14, 249-56	21.7	487
219	Spindle-cell variant of primary cutaneous follicle center lymphoma spreading to the hepatobiliary tree, mimicking Klatskin tumor. <i>Journal of Cutaneous Pathology</i> , 2013 , 40, 56-60	1.7	12
218	Aldara activates TLR7-independent immune defence. <i>Nature Communications</i> , 2013 , 4, 1560	17.4	173
217	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. <i>Nature</i> , 2013 , 494, 251-5	50.4	544
216	Melanoma immunotherapy: historical precedents, recent successes and future prospects. <i>Immunotherapy</i> , 2013 , 5, 169-82	3.8	24
215	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. <i>Lancet Oncology, The</i> , 2013 , 14, 733-40	21.7	135
214	Brief S2k guidelines--Cutaneous lymphomas. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11 Suppl 3, 19-28, 20-30	1.2	22
213	Hypoxia contributes to melanoma heterogeneity by triggering HIF1 α -dependent phenotype switching. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 2436-2443	4.3	97
212	Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy. <i>Journal of Immunotherapy</i> , 2013 , 36, 52-6	5	5
211	Topoisomerase-Interacting Agents 2013 , 170-183		
210	Oral, esophageal and cutaneous lichen ruber planus controlled with alitretinoin: case report and review of the literature. <i>Dermatology</i> , 2013 , 226, 302-10	4.4	20
209	S2k Kurzleitlinie [Kutane Lymphome. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11, 20-30	1.2	4
208	RASopathic skin eruptions during vemurafenib therapy. <i>PLoS ONE</i> , 2013 , 8, e58721	3.7	60
207	Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9004-9004	2.2	2
206	Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9020-9020	2.2	1

205	Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9025-9025	2.2	2
204	Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9028-9028	2.2	24
203	Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20028-e20028	2.2	1
202	The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20050-e20050	2.2	2
201	A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS9105-TPS9105	2.2	2
200	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. <i>PLoS ONE</i> , 2013 , 8, e53745	3.7	343
199	Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9071-9071	2.2	
198	Recent advances in the management of cutaneous lymphomas. <i>Seminars in Oncology</i> , 2012 , 39, 150-62	5.5	5
197	Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). <i>British Journal of Dermatology</i> , 2012 , 167, 678-87	4	60
196	Systematic classification of melanoma cells by phenotype-specific gene expression mapping. <i>Pigment Cell and Melanoma Research</i> , 2012 , 25, 343-53	4.5	113
195	Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1087-99	5.4	21
194	Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4091-7	2.2	67
193	Sorafenib in melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 557-68	5.9	38
192	Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. <i>European Journal of Cancer</i> , 2012 , 48, 1842-52	7.5	60
191	Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. <i>Nature Cell Biology</i> , 2012 , 14, 882-90	23.4	184
190	Improved survival with MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2012 , 367, 107-14	59.2	1634
189	Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540 nm). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 423-30	4.6	13
188	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii86-91	10.3	112

187	Cutaneous lymphomas: molecular pathways leading to new drugs. <i>Journal of Investigative Dermatology</i> , 2012 , 132, 517-25	4.3	10
186	Cutaneous drug eruptions associated with the use of new oncological drugs. <i>Chemical Immunology and Allergy</i> , 2012 , 97, 191-202		18
185	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. <i>Clinical Cancer Research</i> , 2012 , 18, 555-67	12.9	238
184	Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2375-83	2.2	175
183	Ultraviolet A and photosensitivity during vemurafenib therapy. <i>New England Journal of Medicine</i> , 2012 , 366, 480-1	59.2	129
182	Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1501-8	1.9	53
181	First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). <i>Annals of Oncology</i> , 2012 , 23, 531-6	10.3	52
180	Long-term recurrence rate of large and difficult to treat cutaneous squamous cell carcinomas after superficial radiotherapy. <i>Dermatology</i> , 2012 , 224, 59-65	4.4	33
179	Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. <i>Current Opinion in Oncology</i> , 2012 , 24, 150-4	4.2	50
178	Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8076-8076	2.2	1
177	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8502-8502	2.2	65
176	Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8505-8505	2.2	3
175	Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8511-8511	2.2	27
174	Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e19017-e19017	2.2	3
173	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA8509-LBA8509	2.2	10
172	Tumor cell plasticity and angiogenesis in human melanomas. <i>PLoS ONE</i> , 2012 , 7, e33571	3.7	45
171	Analysis of KIT expression and mutations in sinonasal, genital, and acrolentiginous melanomas.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8563-8563	2.2	
170	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8526-8526	2.2	

169	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA8509-LBA8509	2.2	5
168	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). <i>European Journal of Cancer</i> , 2011 , 47, 1476-83	7.5	157
167	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
166	A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 326-33	4.5	56
165	Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 631-42	4.5	72
164	P001. What's the best therapy for treating resected stage III melanoma patients?. <i>Melanoma Research</i> , 2011 , 21, e17	3.3	
163	High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. <i>Blood</i> , 2011 , 117, 2433-40	2.2	63
162	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. <i>Blood</i> , 2011 , 118, 4024-35	2.2	295
161	Successful treatment of multiple keratoacanthoma with topical imiquimod and low-dose acitretin. <i>Journal of Dermatology</i> , 2011 , 38, 390-2	1.6	3
160	Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. <i>Experimental Dermatology</i> , 2011 , 20, 685-8	4	37
159	Evaluation of lymphangiogenic markers in Sjögren syndrome. <i>Leukemia and Lymphoma</i> , 2011 , 52, 491-501	1.9	24
158	Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. <i>Cancer Research</i> , 2011 , 71, 3098-109	10.1	254
157	Clinical end points and response criteria in mycosis fungoides and Sjögren syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2598-607	2.2	407
156	An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 8548-8548	2.2	29
155	Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. <i>Swiss Medical Weekly</i> , 2011 , 141, w13320	3.1	28
154	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. <i>Nature</i> , 2010 , 468, 968-72	50.4	1162
153	Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. <i>Clinical Cancer Research</i> , 2010 , 16, 1058-64	12.9	47
152	Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. <i>Molecular Therapy</i> , 2010 , 18, 1244-7	11.7	33

151	Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro. <i>Virology Journal</i> , 2010 , 7, 175	6.1	6
150	Integrative analysis of the melanoma transcriptome. <i>Genome Research</i> , 2010 , 20, 413-27	9.7	216
149	Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v194-7	10.3	60
148	The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report. <i>Melanoma Research</i> , 2010 , 20, 349-55	3.3	37
147	Melanocytic Tumors 2010 , 169-196		
146	Cutaneous Lymphoma 2010 , 343-354		
145	Basal cell carcinomas: molecular abnormalities and molecularly targeted therapies. <i>Expert Review of Dermatology</i> , 2009 , 4, 355-369		9
144	New and experimental skin-directed therapies for cutaneous lymphomas. <i>Skin Pharmacology and Physiology</i> , 2009 , 22, 322-34	3	19
143	Granulomatous slack skin responds to UVA1 phototherapy. <i>Dermatology</i> , 2009 , 219, 268-71	4.4	12
142	Biomarkers in melanoma. <i>Annals of Oncology</i> , 2009 , 20 Suppl 6, vi8-13	10.3	88
141	Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009 , 20 Suppl 4, 129-31	10.3	26
140	Green tea extract reduces induction of p53 and apoptosis in UVB-irradiated human skin independent of transcriptional controls. <i>Experimental Dermatology</i> , 2009 , 18, 69-77	4	45
139	Long-term pegylated interferon- α ; and its potential in the treatment of melanoma. <i>Biologics: Targets and Therapy</i> , 2009 , 169	4.4	2
138	Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 8572-8572	2.2	7
137	Long-term pegylated interferon-alpha and its potential in the treatment of melanoma. <i>Biologics: Targets and Therapy</i> , 2009 , 3, 169-82	4.4	9
136	The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma--a retrospective analysis of 392 cases. <i>British Journal of Cancer</i> , 2008 , 98, 1922-8	8.7	39
135	A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008 , 22, 1302-11	4.6	163
134	Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. <i>European Journal of Cancer</i> , 2008 , 44, 781-90	7.5	108

133	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet, The</i> , 2008 , 372, 117-126	4.0	496
132	Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1094-103	1.9	63
131	How melanoma is treated in real life. <i>Archives of Dermatology</i> , 2008 , 144, 664-5		4
130	Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography. <i>Dermatology</i> , 2008 , 217, 351-5	4.4	12
129	Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008 , 19 Suppl 2, ii72-6	10.3	32
128	Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). <i>Annals of Oncology</i> , 2008 , 19, 801-6	10.3	21
127	Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008 , 19 Suppl 2, ii86-8	10.3	26
126	Modeling genomic diversity and tumor dependency in malignant melanoma. <i>Cancer Research</i> , 2008 , 68, 664-73	10.1	248
125	Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. <i>Annals of Oncology</i> , 2008 , 19, 1488-1494	10.3	19
124	An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. <i>Clinical Cancer Research</i> , 2008 , 14, 856-64	12.9	89
123	Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. <i>Molecular Therapy</i> , 2008 , 16, 985-94	11.7	38
122	In vivo switching of human melanoma cells between proliferative and invasive states. <i>Cancer Research</i> , 2008 , 68, 650-6	10.1	458
121	European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. <i>Blood</i> , 2008 , 112, 1600-9	2.2	339
120	Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. <i>Melanoma Research</i> , 2008 , 18, 104-11	3.3	26
119	Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. <i>Cancer</i> , 2008 , 113, 1404-11	6.4	18
118	Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL).. <i>Blood</i> , 2008 , 112, 1005-1005	2.2	7
117	Genome Wide Analysis of 41 Mycosis Fungoides Tumor Stage Using Array Comparative Genomic Hybridization Technology.. <i>Blood</i> , 2008 , 112, 1769-1769	2.2	
116	Recent advances in cutaneous lymphomas. <i>Journal of Dermatological Science</i> , 2007 , 48, 157-67	4.3	19

115	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007 , 39, 347-51	36.3	847
114	The optimal use of bexarotene in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2007 , 157, 433-40	4	111
113	Cutaneous lymphomas. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007 , 5, 605-17	1.2	5
112	Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 1366-75	8.8	26
111	Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod. <i>Archives of Dermatological Research</i> , 2007 , 299, 493-8	3.3	19
110	Primary cutaneous lymphomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007 , 18 Suppl 2, ii61-2	10.3	4
109	TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007 , 110, 479-84	2.2	344
108	Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness. <i>Melanoma Research</i> , 2007 , 17, 131-6	3.3	4
107	Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?. <i>European Journal of Cancer</i> , 2007 , 43, 2321-9	7.5	49
106	Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sezary syndrome and role of the bmi-1 and ras oncogenes in disease progression. <i>Human Pathology</i> , 2007 , 38, 995-1002	3.7	21
105	Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007 , 110, 1713-22	2.2	1012
104	Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2834-46	15.9	34
103	Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms. <i>Seminars in Oncology</i> , 2006 , 33, S26-32	5.5	3
102	Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). <i>Seminars in Oncology</i> , 2006 , 33, S33-6	5.5	14
101	Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1188-94	2.2	63
100	Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 865-9	1.9	52
99	EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. <i>European Journal of Cancer</i> , 2006 , 42, 1014-30	7.5	330
98	Standard and experimental therapy in cutaneous T-cell lymphomas. <i>Journal of Cutaneous Pathology</i> , 2006 , 33 Suppl 1, 52-7	1.7	13

97	Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?. <i>Experimental Dermatology</i> , 2006 , 15, 392-400	4	7
96	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. <i>Pigment Cell & Melanoma Research</i> , 2006 , 19, 290-302		378
95	Cutaneous malignant lymphomas: update 2006. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006 , 4, 914-33	1.2	19
94	Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. <i>British Journal of Dermatology</i> , 2006 , 155, 261-6	4	80
93	Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 2525-32	4.3	21
92	Strahlentherapie bñärtiger Hauttumoren 2006 , 135-139		1
91	Elastosis colloidalis conglomerata (adult colloid milium, paracolloid of the skin): a maximal manifestation of actinic elastosis?. <i>European Journal of Dermatology</i> , 2006 , 16, 163-6	0.8	9
90	Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. <i>Dermatology</i> , 2005 , 210, 39-44	4.4	71
89	Emerging drugs in cutaneous T-cell lymphomas. <i>Expert Opinion on Emerging Drugs</i> , 2005 , 10, 381-92	3.7	6
88	Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. <i>Human Gene Therapy</i> , 2005 , 16, 35-48	4.8	119
87	CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. <i>Human Pathology</i> , 2005 , 36, 1020-4	3.7	52
86	Cutaneous melanoma: uncommon presentations. <i>Clinics in Dermatology</i> , 2005 , 23, 587-92	3	6
85	Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. <i>Blood</i> , 2005 , 106, 2287-94	2.2	134
84	HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy. <i>Clinical and Experimental Dermatology</i> , 2005 , 30, 422-5	1.8	23
83	WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. <i>Journal of Cutaneous Pathology</i> , 2005 , 32, 647-74	1.7	271
82	Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9001-7	2.2	95
81	Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1143-53	9.7	158
80	Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides. <i>Dermatology</i> , 2004 , 209, 72-4	4.4	8

79	Survival and prognostic factors in patients with brain metastases from malignant melanoma. <i>Oncology Research and Treatment</i> , 2004 , 27, 145-9	2.8	28
78	Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?. <i>Clinical Cancer Research</i> , 2004 , 10, 4959-70	12.9	31
77	Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. <i>Archives of Dermatology</i> , 2004 , 140, 1490-5		302
76	SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2004 , 150, 252-8	4	26
75	Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. <i>International Journal of Cancer</i> , 2004 , 111, 720-6	7.5	45
74	Role of imiquimod in skin cancer treatment. <i>American Journal of Clinical Dermatology</i> , 2004 , 5, 453-8	7.1	38
73	Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. <i>Blood</i> , 2004 , 104, 1631-8	2.2	94
72	Phase I/II study of adenovirus-interferon- γ (TG1042) in primary cutaneous lymphomas (CL). <i>Journal of Clinical Oncology</i> , 2004 , 22, 3039-3039	2.2	2
71	Phase I/II study of adenovirus-interferon- γ (TG1042) in primary cutaneous lymphomas (CL). <i>Journal of Clinical Oncology</i> , 2004 , 22, 3039-3039	2.2	
70	Clinical and therapeutic aspects of polymorphous light eruption. <i>Dermatology</i> , 2003 , 207, 93-5	4.4	21
69	Therapy of cutaneous lymphoma--current practice and future developments. <i>Oncology Research and Treatment</i> , 2003 , 26, 366-72	2.8	23
68	Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. <i>Blood</i> , 2003 , 102, 2338-44	2.2	112
67	Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. <i>Dermatology</i> , 2003 , 207, 116-8	4.4	55
66	HLA-G and IL-10 expression in human cancer--different stories with the same message. <i>Seminars in Cancer Biology</i> , 2003 , 13, 337-42	12.7	79
65	Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. <i>Cancer</i> , 2003 , 98, 993-1001	6.4	178
64	Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. <i>Cancer</i> , 2003 , 98, 2708-14	6.4	95
63	Hepatitis C and G viruses in B-cell lymphomas of the skin. <i>Journal of Cutaneous Pathology</i> , 2003 , 30, 369-72		22
62	Imiquimod in basal cell carcinoma: how does it work?. <i>British Journal of Dermatology</i> , 2003 , 149 Suppl 66, 57-8	4	60

61	Exploring primary cutaneous B-cell lymphoma by microarray technology. <i>Journal of Investigative Dermatology</i> , 2003 , 120, vii-viii	4.3	1
60	Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more?. <i>British Journal of Dermatology</i> , 2003 , 149, 869-76	4	49
59	HLA-G in skin cancer: a wolf in sheep's clothing?. <i>Human Immunology</i> , 2003 , 64, 1073-80	2.3	15
58	About moles, melanomas, and lasers: the dermatologist's schizophrenic attitude toward pigmented lesions. <i>Archives of Dermatology</i> , 2003 , 139, 1405-6		18
57	Immunotherapy for nonmelanoma skin cancer: does it have a future?. <i>Cancer</i> , 2002 , 94, 477-85	6.4	59
56	CTCL B _h tumour of skin homing T-cells. <i>Experimental Dermatology</i> , 2002 , 11, 483-484	4	2
55	A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. <i>British Journal of Dermatology</i> , 2002 , 146, 1042-6	4	147
54	Junctional CD8+ cutaneous lymphomas with nonaggressive clinical behavior: a CD8+ variant of mycosis fungoides?. <i>Archives of Dermatology</i> , 2002 , 138, 199-203		47
53	HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. <i>Blood</i> , 2002 , 99, 609-17	2.2	137
52	Prevention campaign against skin cancer. <i>Dermatology</i> , 2002 , 205, 229-33	4.4	17
51	Immunomodulators in the treatment of cutaneous lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2002 , 2, 279-86	5.4	6
50	UV protection and skin cancer. <i>Recent Results in Cancer Research</i> , 2002 , 160, 7-12	1.5	21
49	Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myc genes in cutaneous T-cell lymphoma cells. <i>Blood</i> , 2001 , 98, 2778-83	2.2	95
48	Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. <i>Blood</i> , 2001 , 97, 523-7	2.2	27
47	Swiss guidelines for the treatment and follow-up of cutaneous melanoma. <i>Dermatology</i> , 2001 , 203, 75-80	4.4	32
46	Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. <i>Journal of Investigative Dermatology</i> , 2001 , 117, 583-9	4.3	51
45	Diagnostic signs of cutaneous lymphomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001 , 15, 358-360	4.6	
44	TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. <i>International Journal of Cancer</i> , 2001 , 95, 23-8	7.5	56

43	Serological detection of cutaneous T-cell lymphoma-associated antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 629-634	11.5	119
42	Serological detection of cutaneous T-cell lymphoma-associated antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 629-34	11.5	58
41	GVAX (Cell Genesys). <i>Current Opinion in Investigational Drugs</i> , 2001 , 2, 844-8		8
40	Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. <i>Cancer</i> , 2000 , 89, 1835-1844	6.4	98
39	Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. <i>Cancer Gene Therapy</i> , 2000 , 7, 1069-76	5.4	44
38	Melanoma vaccines in development: looking to the future. <i>BioDrugs</i> , 2000 , 13, 227-31	7.9	4
37	Cutaneous T-cell lymphomas: prognosis and quality-of-life issues. <i>Clinical Lymphoma and Myeloma</i> , 2000 , 1 Suppl 1, S21-5		12
36	Pathogenesis of cutaneous lymphomas. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2000 , 19, 78-86	1.4	14
35	Pathogenesis of Cutaneous Lymphomas. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2000 , 19, 78-86	1.4	29
34	Constitutive and Interleukin-7/Interleukin-15 Stimulated DNA Binding of Myc, Jun, and Novel Myc-Like Proteins in Cutaneous T-Cell Lymphoma Cells. <i>Blood</i> , 1999 , 93, 260-267	2.2	46
33	Immunomodulators in the treatment of cutaneous lymphoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1999 , 13, 83-90	4.6	9
32	Genotypic, phenotypic and functional analysis of CD4+CD7+ and CD4+CD7- T lymphocyte subsets in Sjögren syndrome. <i>Archives of Dermatological Research</i> , 1999 , 291, 307-11	3.3	39
31	Inverse regulation of neuronal cellular adhesion molecule (NCAM) by IFN-gamma in melanoma cell cultures established from CNS lesions. <i>International Journal of Cancer</i> , 1999 , 83, 135-40	7.5	11
30	Constitutive and Interleukin-7/Interleukin-15 Stimulated DNA Binding of Myc, Jun, and Novel Myc-Like Proteins in Cutaneous T-Cell Lymphoma Cells. <i>Blood</i> , 1999 , 93, 260-267	2.2	1
29	Immunomodulators in the treatment of cutaneous lymphoma 1999 , 13, 83		1
28	Approach to lymphoproliferative infiltrates of the skin. The difficult lesions. <i>American Journal of Clinical Pathology</i> , 1999 , 111, S84-93	1.9	29
27	Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. <i>Nature Medicine</i> , 1998 , 4, 328-32	50.5	2426
26	Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. <i>Journal of Cutaneous Pathology</i> , 1998 , 25, 204-9	1.7	88

25	Expression of melanoma-associated antigens in short-term melanoma cultures detected by RT-PCR and subsequent ELISA. <i>Archives of Dermatological Research</i> , 1998 , 290, 458-61	3-3	8
24	Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. <i>Journal of Investigative Dermatology</i> , 1998 , 111, 497-502	4-3	54
23	Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma. <i>Academic Radiology</i> , 1998 , 5 Suppl 2, S300-2	4-3	13
22	Pseudo-melanoma after laser therapy. <i>Dermatology</i> , 1998 , 197, 71-3	4-4	63
21	Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. <i>Melanoma Research</i> , 1998 , 8, 337-43	3-3	68
20	Interleukin-15 Is an Autocrine/Paracrine Viability Factor for Cutaneous T-Cell Lymphoma Cells. <i>Blood</i> , 1998 , 92, 252-258	2-2	134
19	Serum S100—a marker for disease monitoring in metastatic melanoma. <i>Dermatology</i> , 1997 , 194, 208-12	4-4	124
18	Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. <i>Journal of Clinical Oncology</i> , 1997 , 15, 2579-88	2-2	172
17	Erysipelas melanomatosum. <i>British Journal of Dermatology</i> , 1997 , 137, 833-4	4	7
16	Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). <i>Blood</i> , 1996 , 88, 1383-1389	2-2	150
15	Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. <i>Archives of Dermatological Research</i> , 1996 , 288, 353-7	3-3	69
14	Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. <i>Archives of Dermatological Research</i> , 1996 , 288, 543-8	3-3	35
13	Malignant blue naevus with distant subcutaneous metastasis. <i>Clinical and Experimental Dermatology</i> , 1996 , 21, 427-30	1-8	18
12	Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid 1996 , 288, 353		11
11	A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. <i>Archives of Dermatology</i> , 1996 , 132, 550-3		2
10	Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). <i>Blood</i> , 1996 , 88, 1383-9	2-2	25
9	Pathology of cutaneous T-cell lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 1995 , 9, 961-953.1		2
8	Peripheral Blood Mononuclear Cells in Patients With Nonleukemic Cutaneous T-Cell Lymphoma. <i>Archives of Dermatology</i> , 1993 , 129, 433		37

7	Soluble interleukin-2 receptors and cutaneous T-cell lymphoma. <i>Cancer</i> , 1993 , 71, 3793-5	6.4	5
6	T cells migrate to tumour sites after extracorporeal interleukin 2 stimulation and reinfusion in a patient with metastatic melanoma. <i>British Journal of Dermatology</i> , 1993 , 128, 399-403	4	7
5	Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. <i>Archives of Dermatology</i> , 1993 , 129, 433-6		5
4	Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. <i>Archives of Dermatology</i> , 1993 , 129, 433-436		45
3	Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. <i>Cancer</i> , 1991 , 67, 2300-4	6.4	37
2	Prognostic significance of DNA cytometry in cutaneous malignant lymphomas. <i>Cancer</i> , 1991 , 68, 1095-1004		11
1	Soluble interleukin-2 receptors and psoriasis. <i>Archives of Dermatological Research</i> , 1991 , 283, 138-9	3.3	2